<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166812</url>
  </required_header>
  <id_info>
    <org_study_id>CAPTO-COPD</org_study_id>
    <nct_id>NCT04166812</nct_id>
  </id_info>
  <brief_title>Change in Airway Peripheral Tone in COPD</brief_title>
  <acronym>CAPTO-COPD</acronym>
  <official_title>Role of Small Airway Dysfunction for Disease Progression in Early COPD - an Observational Two-year Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PD Dr. Henrik Watz, Pulmonary Research Center, LungenClinic Großhansdorf (Principal Investigator)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiesi GmbH, Hamburg, Germany (Funding)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Small airways disease is a pathological feature in mild to moderate COPD, which might be&#xD;
      causally involved in disease progression. However, there are only limited studies available&#xD;
      that prospectively identified patients at risk for small airway disease. Our intention is to&#xD;
      investigate the early phase of the disease. In addition, we thereby want to build up a&#xD;
      well-defined study population of patients in an early phase of the disease with a rapid&#xD;
      decrease in lung function as measured by oscillometry and multiple breath washout&#xD;
      (MBW)-testing. In addition, it is our goal to identify patients in an early stage of disease&#xD;
      and patients at risk of fast progression and/or rapid decline in lung function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oscillometry (change in R5-20)</measure>
    <time_frame>24 months</time_frame>
    <description>change in frequency dependence of resistance (R5-20)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in LCI)</measure>
    <time_frame>24 months</time_frame>
    <description>change in global ventilation heterogeneity (lung clearance index, LCI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in Scond)</measure>
    <time_frame>24 months</time_frame>
    <description>change in conductive ventilation heterogeneity (Scond)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in Sacin)</measure>
    <time_frame>24 months</time_frame>
    <description>change in acinar ventilation heterogeneity (Sacin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>spirometry (change in FEV1)</measure>
    <time_frame>24 months</time_frame>
    <description>change in parameters of central obstruction (forced expiratory volume in one second, FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body plethysmography (change in RV/TLC)</measure>
    <time_frame>24 months</time_frame>
    <description>change in parameters of hyperinflation (residual volume / total lung capacity RV/TLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body plethysmography (change in sRaw)</measure>
    <time_frame>24 months</time_frame>
    <description>change in specific airway resistance (sRaw)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health Status (change in SGRQ-c)</measure>
    <time_frame>24 months</time_frame>
    <description>change in quality of life (SGRQ-c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health Status (change in CAT)</measure>
    <time_frame>24 months</time_frame>
    <description>change in symptom score (CAT)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>COPD</condition>
  <condition>COPD, Early-Onset</condition>
  <arm_group>
    <arm_group_label>patients with early COPD</arm_group_label>
    <description>diagnosis according to current GOLD recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <description>no current diagnosis according to GOLD recommendations, but at risk for COPD</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>oscillometry</intervention_name>
    <description>assessment of peripheral airway resistance using oscillometry</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multiple breath washout testing</intervention_name>
    <description>assessment of ventilation heterogeneity using multiple breath washout testing</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>spirometry</intervention_name>
    <description>assessment of lung function using spirometry</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>body plethysmography</intervention_name>
    <description>assessment of lung function using body plethysmography</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fractional exhaled nitric oxide</intervention_name>
    <description>assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transfer factor</intervention_name>
    <description>assessment of gas transfer using single breath transfer factor for carbon monoxide</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>health status</intervention_name>
    <description>assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT])</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>induced sputum</intervention_name>
    <description>various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  patients at risk for COPD with no current diagnosis according to GOLD recommendations&#xD;
&#xD;
          -  patients with early COPD with diagnosis according to current GOLD recommendations&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        patients at risk for COPD&#xD;
&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  smoking history (at least 10 pack years)&#xD;
&#xD;
          -  absence of airway obstruction (FEV1/FVC ≥ 70% after salbutamol 400µg)&#xD;
&#xD;
          -  high symptom score (CAT ≥ 10) or long acting bronchodilator therapy&#xD;
&#xD;
          -  age &gt; 35 years&#xD;
&#xD;
        exclusion criteria:&#xD;
&#xD;
          -  respiratory infection within 4 weeks prior to inclusion&#xD;
&#xD;
          -  other symptomatic pulmonary disease, except bronchial asthma&#xD;
&#xD;
        patients with early COPD&#xD;
&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  smoking history (at least 10 pack years)&#xD;
&#xD;
          -  mild COPD (FEV1/FVC &lt; 70% and FEV1 ≥ 70% after salbutamol 400µg)&#xD;
&#xD;
          -  age &gt; 35 years&#xD;
&#xD;
        exclusion criteria:&#xD;
&#xD;
          -  respiratory infection within 4 weeks prior to inclusion&#xD;
&#xD;
          -  other pulmonary disease, except bronchial asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Watz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Research Institute at LungClinic Großhansdorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Trinkmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik at Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Research Institute at LungClinic Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik at Heidelberg University</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dr. Frederik Trinkmann</investigator_full_name>
    <investigator_title>Principial Investigator</investigator_title>
  </responsible_party>
  <keyword>small airway disease</keyword>
  <keyword>peripheral airway tone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data protection rules do not allow to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

